Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers

D. Ross Camidge, MD, PhD,of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses research efforts for patients with non–small cell lung cancer who harbor NRG1 fusions.

EP. 1: Prevalence of NRG1 Fusions in Lung Cancer

April 29th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses the prevalence of NRG1 fusions in lung cancer.

EP. 2: Differences Between DNA and RNA Testing for NRG1

April 29th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses differences between DNA and RNA fusions for detecting NRG1 fusions.

EP. 3: Standard Treatments for NRG1 Fusion+ NSCLC

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses standard treatments for patients with non–small cell lung cancer who harbor NRG1 fusions.

EP. 4: Ongoing Research Efforts Targeting NRG1 in Lung Cancer

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses ongoing research for patients with non–small cell lung cancer who harbor NRG1 fusions.

EP. 5: Efficacy With NRG1-Directed Agents in NSCLC

May 6th 2024

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses clinical efficacy with agents targeted for NRG1-fusion–positive non–small cell lung cancer.

EP. 6: Prognosis, Rarity of NRG1+ Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses prognosis and rarity of patients with NRG1 fusion–positive pancreatic cancer.

EP. 7: Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer.

EP. 8: Standard Treatment Regimens for NRG1+ Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses current standard therapeutics for patients with NRG1 fusion–positive pancreatic cancer.

EP. 9: Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.

EP. 10: Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.

EP. 11: DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.

EP. 12: A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.

EP. 13: The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

EP. 14: Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

November 11th 2024

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.

EP. 15: Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

EP. 16: The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.

EP. 17: The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.

EP. 18: Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

EP. 19: Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.

EP. 20: NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers

December 17th 2024

NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.